Tilray Medical Deepens Its European Push at Cannabis Europa

Tilray Medical, the international medical cannabis arm of Tilray Brands (TLRY ), took a Silver Partner slot at Cannabis Europa London 2026, the two-day conference running May 26–27, 2026, at The Barbican in London. The move puts Tilray Medical front and center at one of the most visible European cannabis gatherings at exactly the moment the company is doubling down on Germany and the UK as its clearest paths to growth.

What Tilray Is Doing at the Conference

José Tempero, Tilray Medical’s Director of International Medical Affairs, joined a panel titled “Evidence First: Designing Public Policy (PPHC ) Through Data and Trials” on May 26, 2026. The session brought together regulators, researchers, and industry representatives to examine how European pilot programmes, clinical data, and real-world patient outcomes are shaping the prescribing frameworks that regulators across the continent will ultimately accept. That is not abstract positioning for Tilray: Germany’s expanded patient access following its April 2024 overhaul of its cannabis prescribing framework — which decriminalized cannabis and eliminated the prior restrictive prescription requirements — is the market the company has identified as its primary European growth lever in its public disclosures.

Beyond the main programme, Lyphe Clinic — Tilray Medical’s UK-based medical cannabis clinic and digital patient platform — co-hosted the official Cannabis Europa afterparty on May 27, 2026, at BrewDog Waterloo in London. The decision to present Lyphe alongside the Tilray Medical brand at the conference’s after-hours function is not incidental. Tilray has been assembling a vertically connected UK operation: Lyphe handles consultations, prescription facilitation, patient education, and treatment access, linking directly to Tilray Medical’s supply and distribution infrastructure. Earlier in 2026, the company also announced a UK pharmaceutical distribution agreement with SmartWays, adding a supply-side route alongside the clinic-side patient pathway.

What the Filings Show About the European Bet

Tilray Medical now operates across more than 20 regulated international markets. The conference sponsorship reflects a direction the company has been explicit about in its SEC filings.

Tilray Brands’ quarterly report for the period ended November 30, 2025 — its fiscal second quarter of 2026 — shows international cannabis revenue continuing to grow even as the broader cannabis segment has been under sustained pressure. For all of fiscal 2025, cannabis net revenue fell to $249 million from $272.8 million the prior year, a decline the company attributed in part to permit delays in Portugal and deliberate margin management in Canada. International medical cannabis moved in the opposite direction: Q1 fiscal 2026 international cannabis revenue reached $13.4 million, up 10% year over year. During the Q2 fiscal 2026 earnings call, management described Tilray Medical as running at approximately $150 million in annual revenue. The company’s CC Pharma distribution subsidiary already reaches more than 13,000 German pharmacies, and management stated it was targeting a tripling of Tilray Medical’s Germany distribution footprint during fiscal 2026.

Germany’s patient population for medical cannabis has grown more than fourfold since the April 2024 prescribing framework overhaul, with active patient counts exceeding one million. Winning prescription volume in that market requires exactly the kind of clinical relationships that conference floors and policy panels build — physicians who know the products and the companies behind them. Tilray putting its medical affairs director on a panel about evidence-based policy design is institution-building with a commercial purpose.

The financial backdrop at the parent company level is more complicated. The quarterly filing that shows international revenue growing also shows a $22.3 million operating loss for Q2 fiscal 2026. Tilray Brands remains unprofitable at the operating level. That operating loss is roughly half the $42.2 million loss from the same quarter a year earlier — a measurable improvement the company attributes to restructuring and cost discipline. The European segment is one of the cleaner growth stories in a company still working toward sustained profitability.

What Comes Next

The pieces Tilray is putting together in the UK and Germany — clinic-generated prescription demand, company-produced pharmaceutical-grade product, and distribution infrastructure to move it — describe a vertically oriented European medical cannabis business that does not depend on a single market or regulatory development to work. Lyphe Clinic and the Business of Cannabis Awards shortlist recognition that Tilray received alongside other publicly traded operators this month both point to a company actively working to build European brand credibility at the same time it is building European distribution capacity.

The test — visible in successive quarters of Tilray Brands’ SEC filings — is whether the combination translates into growing prescription volume in Germany and the UK, and whether that international segment can generate the margin improvement the broader company needs to close the gap between its revenue growth and its operating losses.

Latest Tilray (TLRY) Developments

Error fetching company profile. Check if the symbol is valid.